Traphagen Investment Advisors LLC significantly increased its stake in Apple Inc. (NASDAQ:AAPL), making it their 8th largest holding. Many other institutional investors also boosted their Apple holdings, indicating strong institutional confidence despite some insider selling. Analysts maintain a "Moderate Buy" rating for Apple, fueled by positive sentiment around upcoming software changes, AI optimism, and strong financial results, including an increased dividend payment.

Truist Financial Corp significantly reduced its stake in APi Group Corporation by 67.9% in the fourth quarter, now holding 60,989 shares valued at $2.33 million. This comes despite APi Group reporting better-than-expected first-quarter results with strong earnings and revenue. Wall Street analysts maintain a "Moderate Buy" rating for APi Group, with an average price target of $52.14, even with some insider selling noted.

Public Storage, the largest self-storage operator in the US, continues to manage its portfolio performance amidst evolving consumer demands and competitive pressures within the real estate sector. The company operates as a self-administered and self-managed real estate investment trust, specializing in acquiring, developing, and managing self-storage facilities. Its business model relies on recurring rental income and operational efficiency, making it a significant component of the US REIT sector for investors.

Truist Financial Corp significantly increased its stake in Rocket Companies (NYSE:RKT) by 291.9% in the fourth quarter, purchasing an additional 82,873 shares to reach a total of 111,265 shares valued at $2.15 million. Despite this acquisition and Rocket Companies beating first-quarter earnings expectations, the stock has recently fallen by 6.6% to $13.82, trading well below its 52-week high. Analysts currently maintain a consensus "Hold" rating for RKT with a price target of $20.93.

Truist Financial Corp decreased its stake in Ciena Corporation by 15.4% in the fourth quarter, holding 9,559 shares valued at $2.24 million. Despite insider selling totaling $17.4 million, Ciena reported strong quarterly results with $1.35 EPS on $1.43 billion in revenue, surpassing analyst estimates. The company maintains a "Moderate Buy" consensus rating among analysts with an average target price of $367.56.

Argus has raised its price target for First Solar (NASDAQ: FSLR) to $275 from $250, maintaining a buy rating. This upgrade follows the company's strong first-quarter 2026 earnings, which surpassed analyst expectations with an EPS of $3.22 and revenue of $1.04 billion. Despite the positive outlook from Argus, analyst sentiment on First Solar remains mixed, with other firms issuing various ratings and price targets.

Moody's has assigned its top AAA-mf rating to tokenized money market funds offered by Fidelity and BlackRock, affirming their high credit quality, liquidity, and capital preservation. Fidelity's FILQ fund, launched on May 6, utilizes Sygnum's tokenization platform with infrastructure support from JPMorgan Chase, Apex Group, and Chainlink. BlackRock's BUIDL fund, introduced in March 2024, is noted as one of the largest tokenized Treasury funds, contributing to the broader tokenized U.S. government debt market's growth to over $15 billion in assets under management.

Stryker Corp is highlighted as a leading medical technology company, innovating in orthopedics, medsurg, and neurotechnology. The article emphasizes its strong market presence in the US, with a significant revenue base from US hospitals. Stryker's robust financial performance in Q1 2026, driven by its diversified product portfolio and strategic acquisitions, positions it well within the growing global medical devices market.

US Bancorp's shares dropped 3.2% to $52.74 on May 13, 2026, extending a 6.1% weekly decline despite the bank topping Q4 CY2025 earnings estimates with revenue of $7.37 billion and EPS of $1.26. The financial services company, a major US holding company operating in banking, investment, mortgage, trust, and payment services, saw its revenue increase by 5.1% year-over-year. Investors are watching for sustained growth in upcoming quarters amidst economic uncertainties.

Revvity has received FDA clearance for its total testosterone automated chemiluminescence immunoassay (ChLIA) through its Immunodiagnostic Systems (IDS) subsidiary. This new assay, alongside existing tests for free testosterone and sex hormone-binding globulin (SHBG), offers a fully integrated diagnostic approach for testosterone-related disorders on a single platform. This advancement aims to streamline workflow and centralize diagnostics for identifying suspected hypogonadism in men, replacing complex legacy methods.